Legislation intended to limit pharmaceutical manufacturers from reimbursing generic brand drug makers to keep generic versions of patented products off the market was reintroduced in the Senate on January 25.
The Preserve Access to Affordable Generics Act (S 27 [ http://thomas.loc.gov]) would amend the Federal Trade Commission Act and ban “pay-to-delay” agreements between brand name and generic pharmaceutical manufacturers in which a generic drug maker receives anything of value or agrees to limit or forgo research, development, manufacturing, or sales of a generic drug for any period of time.
Mitka M. Delay for Generics. JAMA. 2011;305(10):987. doi:10.1001/jama.2011.263
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: